A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in Combination with Cetuximab and Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma.

Nuttapong Ngamphaiboon Poompis Pattaranutaporn Somthawin Lukerak Teerada Siripoon Artit Jinawath Lalida Arsa Prapimporn Chattranukulchai Shantavasinkul Naphat Taonam Narumol Trachu Natini Jinawath Arpakorn Kositwattanarerk Thiparom Sananmuang Chuleeporn Jiarpinitnun

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The palbociclib, cetuximab and IMRT combination was well-tolerated. The RP2D was established, while no MTD was determined. The regimen demonstrated promising preliminary efficacy, suggesting further investigation is warranted in cisplatin-ineligible p16/HPV-unrelated LA-HNSCC patients.

Keyphrases

end stage renal disease
locally advanced
ejection fraction
newly diagnosed
chronic kidney disease
early stage
peritoneal dialysis
prognostic factors
metastatic colorectal cancer
cell cycle
radiation therapy
metastatic breast cancer
high grade
rectal cancer
cell proliferation
patient reported